regardless of promising clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant resistance from pharmacy benefit managers. The insurers are typically building obstacles to reimbursement, like significant price criteria and prior authorization that restrict patient access. … Read More